Study of CM512 for moderate-to-severe atopic dermatitis
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new treatment called CM512 for people with moderate-to-severe eczema (atopic dermatitis). It aims to see if the drug can improve skin symptoms like itching and rash.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had eczema for at least 1 year.
- Your eczema is moderate to severe (a doctor will assess using scores like EASI and IGA).
- At least 10% of your skin is affected by eczema.
- You have had moderate to severe itching in the past week (score 4 or higher on a 0-10 scale).
- You are not pregnant, and you have no other medical conditions that could affect the trial results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This study tests a new medication called IBI3033 for people with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with skin creams alone. The goal is to see if this drug can safely reduce itching, inflammation, and affected skin area.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
This study tests whether a new medication called ENV-294 can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to other treatments. The trial will check if the drug reduces itching and skin inflammation safely.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.